Provision of laboratory services for lipid analysis in the United Kingdom

Annals of Clinical Biochemistry

Volumn 44, Issue 3, 2007, Pages 273-280

  Hutchesson, A C J ^a   O'Kane, M J ^b   Neely, R D ^c   Oleesky, D A ^d  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CLINICAL CHEMISTRY; CLINICAL LABORATORY; DIET RESTRICTION; HEALTH SERVICE; LABORATORY PERSONNEL; LABORATORY TEST; LIPID ANALYSIS; MEDICAL AUDIT; MEDICAL STAFF; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SECONDARY PREVENTION; STANDARD; UNITED KINGDOM; VALIDATION PROCESS; BLOOD; CLASSIFICATION; HUMAN; LABORATORY; ORGANIZATION AND MANAGEMENT;

GREAT BRITAIN; GUIDELINES; HUMANS; LABORATORIES; LIPIDS; QUESTIONNAIRES;

EID: 34250356430     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456307780480891     Document Type: Article

References (31)

1. National Institute for Health and Clinical Excellence. Technology appraisal 94. Statins for the prevention of cardiovascular events, 2006. http://www.nice.org.uk
2. Abbott RD, McGee DL. Section 37: The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel WB, Woolf PA, Garrison RJ, eds. The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease. DHEW Publication number (NIH) 887-2284. Bethesda, MD: Public Health Service, 1987
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; ii: 933-6
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on cholesterol events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
9. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
10. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
11. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-81
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-18
13. Birjmohun RS, Hutten BA, Kastelein JJP, et al. Efficacy and safety of high-density lipoprotein cholesterol increasing compounds. A meta-analysis of randomised controlled trials. Am J Coll Cardiol 2005; 45: 185-97
14. Department of Health. National Service Framework for Coronary Heart Disease. Modern Standards and Service Models. London: Department of Health (England), 2000
15. Scottish Executive Coronary Heart Disease and Stroke: Strategy for Scotland. Edinburgh: Scottish Executive, 2002. http://www.scotland.gov.uk/ Publication/2002/10/15530/11612
16. National Service Framework. Tackling Coronary Heart Disease in Wales: Implementing Through Evidence. Cardiff: National Assembly for Wales, 2001
17. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71
18. Ramsay LE, Haq IU, Jackson PR. et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield Table. Lancet 1996; 348: 387-8
19. Wood DA, Durrington P, Poulter N, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80: S1-29
20. Scottish Intercollegiate Guidelines Network. SIGN publication no. 40. Lipids and the primary prevention of coronary heart disease, 1999. http://www.sign.ac.uk
21. British Medical Association. New GMS contract 2003. Quality indicators - summary of points: secondary prevention in coronary heart disease. http:/www.bma.org.uk
22. Wood D, Wray R, Poulter N. et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl V): v1-52
23. Hassan AM, Hutchesson AJ. Assessment of lipid-profile services in North-West and Mersey regions of England. In: Martin SM, ed. Proceedings of the ACB National Meeting. Manchester: Association of Clinical Biochemists, 2003: 44-5
24. All Wales Clinical Biochemistry Audit Group. Standards for the provision and reporting of lipid analyses. May 2005; http://www.acbwales.org.uk/audit/ guidelines/lipid_analysis.pdf
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
26. Boyle R. National Policy on Statin Prescribing. Department of Health, 2006. http://www.heart.nhs.uk/scripts/default.asp?site_id=23&id=5453
27. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
28. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526-9
29. Smellie WSA. Testing pitfalls and summary of guidance in lipid management. BMJ 2006; 333: 83-6
30. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects measured in the fed and fasted states. Clin Chem 1988; 34: 2456-9
31. Department of Health. Report of the Review of NHS Pathology Services in England. London: Department of Health (England), 2006